CORAL GABLES, Fla., Aug. 15, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the second quarter and six months ended June 30, 2012. For the three months ended June 30, 2012, the Company reported a net loss of $289,080, or $0.01 per basic and diluted share, compared to a net loss of $1,394,151, or $0.06 per basic and diluted share, for the same period in 2011. For the six months ended June 30, 2012, the Company reported a net loss of $1,378,266, or $0.05 per basic and diluted share, compared to a net loss of $2,911,287, or $0.14 per basic and diluted share, for the same period in 2011.
Research and development expenses for the second quarter of 2012 were $532,741, compared to $905,635 in the second quarter of 2011. Research and development expenses for the six months ended June 30, 2012 were $1,260,068 compared to $1,809,588 for the first six months of 2011. Research and development expenses decreased when compared to the same period in 2011, as expenses incurred during the six month period ended June 30, 2011 included pre-clinical studies and drug development activities for CPP-115 in connection with the submission of an IND for CPP-115 (which occurred during the fourth quarter of 2011). General and administrative expenses for the second quarter of 2012 totaled $534,623, compared to $491,828 in the second quarter of 2011. General and administrative expenses for the first six months of 2012 totaled $1,172,006 compared to $1,107,125 in the first six months of 2011. Other income for the second quarter and six months ended June 30, 2012 was $778,284 and $1,053,808, respectively, compared to $3,312 and $5,426 for the same periods in 2011. These fluctuations were primarily due to non-cash changes in the fair value of the Company's outstanding warrants liability.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV